The Short Version
The claim assigns the 15 mg dose’s weight-loss result to the 5 mg dose. At week 72 of the Phase 3 SURMOUNT-1 trial, mean body-weight change was −15.0% with once-weekly 5 mg tirzepatide; −20.9% was the result for 15 mg. The peer-reviewed trial report and FDA records, including the January 2026 label, consistently document this distinction.